Laurus Labs Ltd (540222) closes at ₹400.30 with
a Gain of
+2..10% on 07-Aug-2023 with formation
of a bullish Green candle on Daily Price Chart.
About the Company : Founded
in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology
company having a global leadership
position in select Active Pharmaceutical
Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent
APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO
and CDMO services to Global Innovators from Clinical phase drug development to
commercial manufacturing.
Laurus employs 6500+ people, including around
1050+ scientists at more than 11 facilities approved by global agencies USFDA,
WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc.
Sector Update : Positive
Refinitiv
Average Score : 2/ 10
Financials : Laurus Labs Ltd has posted
Net Sales / Revenue of ₹6040.60 Cr & Net Profit of ₹790.10 Cr in FY2023 and expected to post Net
Sales / Revenue of ₹5885.30 Cr & Net Profit of ₹567.30 Cr in FY2024, Net Sales /
Revenue of ₹6756.60 Cr & Net Profit of ₹1838.70 in FY2025 and Net Sales /
Revenue of ₹7666.60 Cr & Net Profit of ₹1104.90 Cr in FY20.26.
Valuations :
The Company is now Trading at X2.90 of
its valuations
of FY2023 (Last 4 Quarters ) earnings with ~190% premium
; at X2.73 of its FY2024 earnings with ~173% Premium
; at X1.85 of its FY2025 earnings with ~85% Premium and at X1.40 of
its FY2026 earnings with ~40% Premium
Company will reduce its total debt of ₹1923.50 Cr in FY 2023 to ₹1736.60 by FY 2026
along with Improvement in Net Margin from 13.10 (FY2023) to 14.40% ( FY2026).
Book Value Per
Share will improve from ₹75.00 in FY2023 to ₹107.00 in FY2026 and EPS from 14.60 to 20.60 .
Early Trend : Huge
Capex in FY2024 for CDMO
Business.
MF/FII
: 2.70% MF Holding & 5.40% FII Holding
Margin of Safety (1Yr Bond Yield: Value>1 ) is
now 0.4 which will increase in FY2024-25.The Equity
Value Per Share ( Enterprise Value Method ) is ₹400.30 If We factor its FY2026 earnings/valuations, relative to
current valuations, its Price arrives
at ₹826.00
Disclaimer : We are / may going to take exposure
shortly.
Join Us
at Telegram # https://t.me/TheNiftyNext
Data Source | NSE Website | Screener.In | Capital Line | Money
Control |Refinitiv |
The author tracks economic,
behavioural and corporate tends, hoping to gauge good avenues of return based
on Fundamental Valuations of Stocks, a follower of EPV method. You can reach me/us at | Twitter # NiftyNext1
| e-Mail : Mail@NiftyNext.Com | Tel +91
8802230836 | Telegram # TheNiftyNext Manage your investments the right
way With MProfit. Visit https://www.mprofit.inUse
Our Referral Link to Get 20% DISCOUNT @ https://www.mprofit.in/buy?referral=R1GD99J496AB1345D